JPRN-UMIN000031317招募中2 期
Phase II study of TAS-102 plus bevacizumab as maintenance therapy after induction chemotherapy with bevacizumab, oxaliplatin, and fluoropyrimidine in patients with metastatic colorectal cancer - Switch Maintenance Study
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group0 个研究点目标入组 55 人开始时间: 2018年2月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Prior treatment with TAS-102 and Bevacizumab. 2) Previous or concurrent cancer that is distinct in primary site or histology form colorectal cancer within 1 years prior to EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta, Tis and T1]. 3) Major surgical procedure within 28 days before start of study medication. 4) Pregnant or breast-feeding patients. Woman of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment. 5)Congestive heart failure >=NYHA class 2. 6) Unstable angina, new-onset angina. Myocardial infarction less than 6 months before start of study medication. 7)Uncontrolled hypertension. 8) Pleural effusion or ascites with dyspnea higher than CTCAE v4.0 grade 2. 9) Arterial or venous thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication. 10) Known history of HIV infection, or chronic hepatitis B or C. 11) Symptomatic metastatic brain or meningeal metastasis. 12) Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event >= CTCAE v4.0 Grade 3 within 4 weeks of start of study medication. 13) Interstitial lung disease with ongoing signs and symptoms at the time of informed consent. 14) Persistant proteinuria of CTCAE v4.0 Grade 3 or higher. 15) Patients unable to swallow oral medications. 16) Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation. 17) Non-healing wound, ulcer, or bone fracture. 18) Unsolved toxicity higher than CTCAE v4.0 Grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity <= Grade 2. 19) A responsible doctor has confirmed the candidate should be excluded from this study.
研究者
相似试验
招募中
2 期
Switch Maintenance StudyColorectal cancerJPRN-jRCT1051180117emura Mamoru55
已完成
2 期
A phase II study of TAS-102 plus Bevacizumab therapy for advanced/recurrent colorectal cancer with difficulty on intensive chemotherapyColorectal CancerJPRN-UMIN000022705Osaka medical Center for Cancer and Cardiovascular Diseases20
招募中
2 期
Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidineColorectal CancerJPRN-UMIN000026043Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery28
尚未招募
2 期
TAS-102 plus Bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer, phase 2 trialmetastaic colorectal cancerJPRN-UMIN000020240Tokushima University Hospital30
尚未招募
2 期
TAS-102 plus Bevacizumab combination as salvage therapy in elderly patients with metastatic colorectal cancer, phase 2 trialmetastatic colorectal cancerJPRN-UMIN000021664Tokushima University Hospital25